Thomas G Wiggans's Net Worth
$14.6 Million
Who is Thomas G Wiggans?
Thomas G Wiggans has an estimated net worth of $14.6 Million. This is based on reported shares across multiple companies, which include CymaBay Therapeutics, Inc., PEPLIN INC, TERCICA INC, SANGAMO BIOSCIENCES INC, PARDES BIOSCIENCES, INC., Forma Therapeutics Holdings, Inc., Dermira, Inc., Annexon, Inc., ONYX PHARMACEUTICALS INC, Somaxon Pharmaceuticals, Inc., Jasper Therapeutics, Inc., ABGENIX INC, and CONNETICS CORP.
SEC CIK
Thomas G Wiggans's CIK is 0001208907
Past Insider Trading and Trends
2017 was Thomas G Wiggans's most active year for acquiring shares with 24 total transactions. Thomas G Wiggans's most active month to acquire stocks was the month of February. 2017 was Thomas G Wiggans's most active year for disposing of shares, totalling 37 transactions. Thomas G Wiggans's most active month to dispose stocks was the month of July. 2017 saw Thomas G Wiggans paying a total of $6,175,184.00 for 330,000 shares, this is the most they've acquired in one year. In 2006 Thomas G Wiggans cashed out on 1,319,690 shares for a total of $11,906,847.25, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
CymaBay Therapeutics, Inc. (CBAY) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 22
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 24
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 5
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
PEPLIN INC No price found
CEO and Chairman the Board
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| +0.22% | 500 |
$10.00 | $5,000.00 | 227.82K |
Jan 14
| |||
Form 4
| +0.22% | 500 |
$3.95 | $1,973.00 | 227.32K |
Nov 19
| |||
Form 4
| +0.22% | 500 |
$6.00 | $3,000.00 | 226.82K |
Nov 10
| |||
Form 4
| +17,058.38% | 225K |
—
|
—
| 226.32K |
Nov 6
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
TERCICA INC No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 18
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
SANGAMO BIOSCIENCES INC (SGMO) Snapshot price: $0.72
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 4
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
PARDES BIOSCIENCES, INC. No price found
Chief Executive Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -50.00K |
—
|
—
|
0
|
Aug 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 1
| |||
Form 4
| +33.33% | 12.5K |
$1.09 | $13,625.00 | 50K |
Dec 5
| |||
Form 4
|
∞
| 37.5K |
$1.05 | $39,375.00 | 37.5K |
Dec 1 - Dec 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 2
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |